Abstract
The ErbB family blockers, afatinib and dacomitinib, and the third-generation EGFR TKI, osimertinib, confer significant clinical benefit versus first-generation EGFR TKIs (erlotinib and gefitinib) in patients with EGFR mutation-positive (EGFRm+) NSCLC. However, no prospective data exist directly comparing afatinib, dacomitinib and osimertinib. In terms of overall survival (OS), outcomes are highly dependent on the availability and implementation of subsequent therapy following acquired resistance to first-line therapy.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
